- Home
- MVST vs DNTH Comparison
MVST vs DNTH Comparison
Compare MVST & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MVST
- DNTH
- Stock Information
- Founded
- MVST 2006
- DNTH 2015
- Country
- MVST United States
- DNTH United States
- Employees
- MVST N/A
- DNTH N/A
- Industry
- MVST Industrial Machinery/Components
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- MVST Miscellaneous
- DNTH Health Care
- Exchange
- MVST Nasdaq
- DNTH Nasdaq
- Market Cap
- MVST 680.5M
- DNTH 657.0M
- IPO Year
- MVST N/A
- DNTH N/A
- Fundamental
- Price
- MVST $3.57
- DNTH $17.53
- Analyst Decision
- MVST Strong Buy
- DNTH Strong Buy
- Analyst Count
- MVST 1
- DNTH 8
- Target Price
- MVST $3.00
- DNTH $53.00
- AVG Volume (30 Days)
- MVST 11.6M
- DNTH 255.5K
- Earning Date
- MVST 05-12-2025
- DNTH 05-12-2025
- Dividend Yield
- MVST N/A
- DNTH N/A
- EPS Growth
- MVST N/A
- DNTH N/A
- EPS
- MVST N/A
- DNTH N/A
- Revenue
- MVST $414,941,000.00
- DNTH $6,524,000.00
- Revenue This Year
- MVST $25.99
- DNTH N/A
- Revenue Next Year
- MVST $29.81
- DNTH N/A
- P/E Ratio
- MVST N/A
- DNTH N/A
- Revenue Growth
- MVST 21.68
- DNTH 102.36
- 52 Week Low
- MVST $0.15
- DNTH $13.37
- 52 Week High
- MVST $4.32
- DNTH $32.27
- Technical
- Relative Strength Index (RSI)
- MVST 63.71
- DNTH 37.32
- Support Level
- MVST $3.74
- DNTH $16.91
- Resistance Level
- MVST $4.32
- DNTH $18.45
- Average True Range (ATR)
- MVST 0.43
- DNTH 1.14
- MACD
- MVST -0.00
- DNTH -0.20
- Stochastic Oscillator
- MVST 58.79
- DNTH 17.97
About MVST Microvast Holdings Inc.
Microvast Holdings Inc is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions. It is renowned for its cutting-edge cell technology and its vertical integration capabilities which extends from core battery chemistry to battery packs.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.